Immune Cell Trafficking in Inflammatory Bowel Diseases
Trafficking of immune cells to the gut appears to be an important pathway for the onset and maintenance of dysregulated inflammation seen in IBD. In fact, interference with immune cell migration to the gut is a fruitful therapeutic approach. However, a significant proportion of patients experience primary non-response or secondary loss of response. Therefore, exploration of immune-related biomarkers predicting treatment response in patients with IBD is, hypothetically, the next step towards treatment personalisation, thereby increasing treatment effectiveness, minimizing disease burden, and lowering societal healthcare costs.